These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 38863635)
41. CAR-NK cell in cancer immunotherapy; A promising frontier. Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690 [TBL] [Abstract][Full Text] [Related]
42. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology. Schmidt P; Raftery MJ; Pecher G Front Immunol; 2020; 11():611163. PubMed ID: 33488617 [TBL] [Abstract][Full Text] [Related]
43. Engineering the next generation of CAR-NK immunotherapies. Biederstädt A; Rezvani K Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686 [TBL] [Abstract][Full Text] [Related]
44. CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future. Zhang L; Meng Y; Yao H; Zhan R; Chen S; Miao W; Ma S; Xu X; Li Y; Yu M; Han Y; Su W; Han Z; Wang T; Song B; Wang P; Cai H; Yan J Am J Cancer Res; 2023; 13(11):5559-5576. PubMed ID: 38058830 [TBL] [Abstract][Full Text] [Related]
45. Natural killer cells: a promising immunotherapy for cancer. Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854 [TBL] [Abstract][Full Text] [Related]
46. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. Zhang B; Yang M; Zhang W; Liu N; Wang D; Jing L; Xu N; Yang N; Ren T Cell Death Dis; 2024 Jan; 15(1):50. PubMed ID: 38221520 [TBL] [Abstract][Full Text] [Related]
47. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Bashiri Dezfouli A; Yazdi M; Pockley AG; Khosravi M; Kobold S; Wagner E; Multhoff G Cells; 2021 Dec; 10(12):. PubMed ID: 34943898 [TBL] [Abstract][Full Text] [Related]
49. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457 [TBL] [Abstract][Full Text] [Related]
50. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203 [No Abstract] [Full Text] [Related]
51. Purinergic targeting enhances immunotherapy of CD73 Wang J; Lupo KB; Chambers AM; Matosevic S J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403 [TBL] [Abstract][Full Text] [Related]
52. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234 [TBL] [Abstract][Full Text] [Related]
53. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. Pan C; Zhai Y; Li G; Jiang T; Zhang W Front Oncol; 2021; 11():751183. PubMed ID: 34765554 [TBL] [Abstract][Full Text] [Related]
54. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies. Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584 [TBL] [Abstract][Full Text] [Related]
55. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Hu Y; Tian ZG; Zhang C Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014 [TBL] [Abstract][Full Text] [Related]
56. Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report. Zhang X; Guo Y; Ji Y; Gao Y; Zhang M; Liu Y; Zhu W; Lu P Cell Transplant; 2022; 31():9636897221094244. PubMed ID: 35506155 [TBL] [Abstract][Full Text] [Related]
57. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751 [TBL] [Abstract][Full Text] [Related]
58. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806 [No Abstract] [Full Text] [Related]
59. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]
60. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy. Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M Cells; 2024 Mar; 13(5):. PubMed ID: 38474415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]